Intelligent Omics Ltd. has established a target discovery collaboration with Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to evaluate novel biological targets for the treatment of hematological cancers.
The Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI) have announced a renewed collaboration to accelerate the development of vaccines against emerging infectious diseases.
Monoacylglycerol lipase (MAGL), a member of the serine hydrolase family expressed in the brain and peripheral tissue, is a key enzyme in the hydrolysis of monoglycerides, converting 2-arachidonoyl glycerol (2-AG) into arachidonic acid and glycerol. MAGL inhibition has been previously shown to induce anxiolytic and analgesic phenotypes in animal models. Researchers from Janssen Pharmaceutica NV recently reported the discovery of novel noncovalent MAGL inhibitors.
Researchers have demonstrated that inhibiting mitophagy in ‘old’ hematopoietic stem cells (HSCs) completely restored their blood reconstitution capabilities, raising the prospect of addressing the age-related weakening of the immune system that stems from HSCs deteriorating over time.
A Pelemed Co. Ltd. patent details new indirubin derivatives acting as inhibitors of FLT3 (FLK2/STK1) and/or proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) and its mutants. They are reported to be useful for the treatment of acute myeloid leukemia.
Research at Pharos Ibio Co. Ltd. has led to the identification of son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer.
Gilead Sciences Inc. and Novartis AG have jointly reported pyrazolopyridinone compounds potentially useful for the treatment of herpes virus infections.
Aurigene Oncology Ltd. has reported the discovery of proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding agent coupled to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety via linker. They act as SMARCA2 and/or SMARCA4 degradation inducers and are reported to be useful for the treatment of cancer.
RSS
